Grunenthal GmbH-Strategic SWOT Analysis Review
- GDPH132572SA
- Pages: 35
- August 2017
- Region : Europe
- GlobalData
- Equity Research Report

- Details
- Table Of Content
- Licence Rights
- Section Purchase
- Products and Companies
Details
Grunenthal GmbH-Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Business description-A detailed description of the company's operations and business divisions.
Corporate strategy-GlobalData's summarization of the company's business strategy.
SWOT analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history-Progression of key events associated with the company.
Major products and services-A list of major products, services and brands of the company.
Key competitors-A list of key competitors to the company.
Key employees-A list of the key executives of the company.
Executive biographies-A brief summary of the executives' employment history.
Key operational heads-A list of personnel heading key departments/functions.
Important locations and subsidiaries-A list of key locations and subsidiaries of the company, including contact details.
Key manufacturing facilities-A list of key manufacturing facilities of the company.
Highlights
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. The company researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. It provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal focuses on discovering new methods to treat pain and developing new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Australia, Latin America and the US. It has production plants in Germany, Italy, Switzerland and Ecuador. Grunenthal is headquartered in Aachen, Germany.
Grunenthal GmbH Key Recent Developments
Jul 07,2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)
May 23,2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects
May 10,2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward
May 09,2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal
May 03,2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients
Reasons to Buy
Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1-About the Company 5
Grunenthal GmbH-Key Facts 5
Grunenthal GmbH-Key Employees 6
Grunenthal GmbH-Key Employee Biographies 7
Grunenthal GmbH-Major Products and Services 8
Grunenthal GmbH-History 9
Grunenthal GmbH-Company Statement 10
Grunenthal GmbH-Locations And Subsidiaries 11
Head Office 11
Other Locations & Subsidiaries 11
Section 2-Company Analysis 14
Grunenthal GmbH-Business Description 14
Grunenthal GmbH-Corporate Strategy 15
Grunenthal GmbH-SWOT Analysis 16
SWOT Analysis-Overview 16
Grunenthal GmbH-Strengths 16
Grunenthal GmbH-Weaknesses 17
Grunenthal GmbH-Opportunities 18
Grunenthal GmbH-Threats 19
Grunenthal GmbH-Key Competitors 20
Section 3-Company's Lifesciences Financial Deals and Alliances 21
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 22
Grunenthal GmbH, Recent Deals Summary 23
Section 4-Company's Recent Developments 24
Jul 07, 2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 24
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 25
May 10, 2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 26
May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 27
May 03, 2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients 28
Oct 04, 2016: Gabriel Baertschi Takes Office as New CEO of Grunenthal Group as of October 1, 2016 29
Sep 27, 2016: A Research Consortium Under the Direction of Grunenthal Will Receive a Grant of EUR1.5 million From the European Fund for Regional Development and the Federal State of North Rhein-Westphalia 30
Jun 23, 2016: EFIC-Grunenthal Grant 2016 32
Jun 07, 2016: Grunenthal Appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer Effective October 1, 2016 33
Mar 03, 2016: Drug Discovery Collaboration between Grunenthal and Axxam 34
Section 5-Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List Of Figure
List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 22
List Of Table
List of Tables
Grunenthal GmbH, Key Facts 5
Grunenthal GmbH, Key Employees 6
Grunenthal GmbH, Key Employee Biographies 7
Grunenthal GmbH, Major Products and Services 8
Grunenthal GmbH, History 9
Grunenthal GmbH, Other Locations 11
Grunenthal GmbH, Subsidiaries 11
Grunenthal GmbH, Key Competitors 20
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 22
Grunenthal GmbH, Recent Deals Summary 23
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
Products and Companies
Products
Grunenthal GmbH, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Overview, Key Manufacturing Facilities, Key Information, Overview, Business Description, Major Products and Services, Brands, History, Key Employees, Key Employee Biographies, Key Operational Heads, Locations And Subsidiaries, Competitors, Company Statement.
Grunenthal GmbH-Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Business description-A detailed description of the company's operations and business divisions.
Corporate strategy-GlobalData's summarization of the company's business strategy.
SWOT analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history-Progression of key events associated with the company.
Major products and services-A list of major products, services and brands of the company.
Key competitors-A list of key competitors to the company.
Key employees-A list of the key executives of the company.
Executive biographies-A brief summary of the executives' employment history.
Key operational heads-A list of personnel heading key departments/functions.
Important locations and subsidiaries-A list of key locations and subsidiaries of the company, including contact details.
Key manufacturing facilities-A list of key manufacturing facilities of the company.
Highlights
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. The company researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. It provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal focuses on discovering new methods to treat pain and developing new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Australia, Latin America and the US. It has production plants in Germany, Italy, Switzerland and Ecuador. Grunenthal is headquartered in Aachen, Germany.
Grunenthal GmbH Key Recent Developments
Jul 07,2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)
May 23,2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects
May 10,2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward
May 09,2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal
May 03,2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients
Reasons to Buy
Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1-About the Company 5
Grunenthal GmbH-Key Facts 5
Grunenthal GmbH-Key Employees 6
Grunenthal GmbH-Key Employee Biographies 7
Grunenthal GmbH-Major Products and Services 8
Grunenthal GmbH-History 9
Grunenthal GmbH-Company Statement 10
Grunenthal GmbH-Locations And Subsidiaries 11
Head Office 11
Other Locations & Subsidiaries 11
Section 2-Company Analysis 14
Grunenthal GmbH-Business Description 14
Grunenthal GmbH-Corporate Strategy 15
Grunenthal GmbH-SWOT Analysis 16
SWOT Analysis-Overview 16
Grunenthal GmbH-Strengths 16
Grunenthal GmbH-Weaknesses 17
Grunenthal GmbH-Opportunities 18
Grunenthal GmbH-Threats 19
Grunenthal GmbH-Key Competitors 20
Section 3-Company's Lifesciences Financial Deals and Alliances 21
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 22
Grunenthal GmbH, Recent Deals Summary 23
Section 4-Company's Recent Developments 24
Jul 07, 2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 24
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 25
May 10, 2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 26
May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 27
May 03, 2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients 28
Oct 04, 2016: Gabriel Baertschi Takes Office as New CEO of Grunenthal Group as of October 1, 2016 29
Sep 27, 2016: A Research Consortium Under the Direction of Grunenthal Will Receive a Grant of EUR1.5 million From the European Fund for Regional Development and the Federal State of North Rhein-Westphalia 30
Jun 23, 2016: EFIC-Grunenthal Grant 2016 32
Jun 07, 2016: Grunenthal Appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer Effective October 1, 2016 33
Mar 03, 2016: Drug Discovery Collaboration between Grunenthal and Axxam 34
Section 5-Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List Of Figure
List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 22
List Of Table
List of Tables
Grunenthal GmbH, Key Facts 5
Grunenthal GmbH, Key Employees 6
Grunenthal GmbH, Key Employee Biographies 7
Grunenthal GmbH, Major Products and Services 8
Grunenthal GmbH, History 9
Grunenthal GmbH, Other Locations 11
Grunenthal GmbH, Subsidiaries 11
Grunenthal GmbH, Key Competitors 20
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 22
Grunenthal GmbH, Recent Deals Summary 23
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Products
Grunenthal GmbH, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Overview, Key Manufacturing Facilities, Key Information, Overview, Business Description, Major Products and Services, Brands, History, Key Employees, Key Employee Biographies, Key Operational Heads, Locations And Subsidiaries, Competitors, Company Statement.